Abbott Laboratories (ABT) Free Cash Flow (2009 - 2026)

Abbott Laboratories (ABT) has 18 years of Free Cash Flow data on file, last reported at $916.0 million in Q1 2026.

• For the quarter ending Q1 2026, Free Cash Flow fell 1.82% year-over-year to $916.0 million; the trailing twelve-month figure through Mar 2026 stood at $7.4 billion (up 10.83% YoY), and the FY2025 full-year result was $7.4 billion, up 16.44% from the prior year.
• Free Cash Flow slipped to $916.0 million in Q1 2026, from $2.6 billion in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of $2.6 billion in Q4 2025 to a low of $627.0 million in Q1 2024.
• A 5-year average of $1.6 billion and a median of $1.7 billion in 2022 frame the typical range for Free Cash Flow.
• Across the five-year window, Free Cash Flow sank 65.73% in 2023 and jumped 105.03% in 2024, its largest moves.
• Tracing ABT's Free Cash Flow over 5 years: stood at $1.7 billion in 2022, then jumped by 33.04% to $2.3 billion in 2023, then slipped by 5.91% to $2.1 billion in 2024, then rose by 22.25% to $2.6 billion in 2025, then tumbled by 65.12% to $916.0 million in 2026.
• Business Quant data shows ABT's Free Cash Flow at $916.0 million in Q1 2026, $2.6 billion in Q4 2025, and $2.3 billion in Q3 2025.